BRD4 and neoplasm: BET bromodomain inhibitors like JQ1 and I-BET726 displace BRD4 from the MYCN promoter, leading to improved survival in various in vivo neuroblastoma models by inhibiting tumor growth and MYCN downregulation [209, 210].